Testosterone Levels Do Not Decline with Age in Healthy Men

Abstract

Aim: To establish norms for reproductive hormones in healthy males with normal urologic and sexual function, and to assess the change in reproductive hormone levels with respect to age among healthy males. Methods: Healthy volunteers aged 18 - 29 (group 1) and 45 - 65 (group 2) were recruited for enrollment in a prospective study. Inclusion criteria comprised normal urinary, ejaculatory, orgasmic, and erectile function, as determined by IPSS, MSHQ, and IEFF-15. Men with history of chronic medical illnesses or chronic medication use were excluded. Fifty men met the study criteria. Each participant underwent physical examination and standardized serum hormone evaluation using ELISA and EIA methods. Statistical analysis was performed using JMP 8.0 software (SAS Institute Inc., Cary, NC), to compare hormone levels between the two groups of men. Results: There were 25 men each in groups 1 (mean age 26) and 2 (mean age 51). Overall, 46% were Caucasian, 31% African American, 15% Hispanic, and 8% Asian. There was no statistically significant difference in serum total T, SHBG, E2, or LH between groups 1 and 2. Notably, the 95% CI for serum T levels for both groups of men were considerably higher than commonly accepted lower-end cut-off limits. Conclusion: Serum T levels do not vary significantly with age, in otherwise healthy men with normal sexual and urologic function. Furthermore, healthy men have much higher serum total and free T levels than the lower-end reference limits provided by commercial laboratories.

Share and Cite:

A. Mehta, A. Bolyakov, R. Sultan, L. Vaucher, A. Mielnik, J. Kiper and D. Paduch, "Testosterone Levels Do Not Decline with Age in Healthy Men," Open Journal of Urology, Vol. 3 No. 4, 2013, pp. 173-178. doi: 10.4236/oju.2013.34032.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] S. M. Harman, et al., “Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men. Baltimore Longitudinal Study of Aging,” The Journal of Clinical Endocrinology & Metabolism, Vol. 86, No. 2, 2001, pp. 724-731. doi:10.1210/jc.86.2.724
[2] E. L. Rhoden and A. Morgentaler, “Risks of Testosterone-Replacement Therapy and Recommendations for Monitoring,” The New England Journal of Medicine, Vol. 350, No. 5, 2004, pp. 482-492. doi:10.1056/NEJMra022251
[3] S. Bhasin and J. G. Buckwalter, “Testosterone Supplementation in Older Men: A Rational Idea Whose Time Has not yet Come,” Journal of Andrology, Vol. 22, No. 5, 2001, pp. 718-731.
[4] J. L. Tenover, “Male Hormone Replacement Therapy Including Andropause,” Endocrinology and Metabolism Clinics of North America, Vol. 27, No. 4, 1998, pp. 969-987. doi:10.1016/S0889-8529(05)70050-5
[5] P. P. J. Snyder, et al., “Effects of Testosterone Replacement in Hypogonadal Men,” The Journal of Clinical Endocrinology & Metabolism, Vol. 85, No. 8, 2000, pp. 2670-2677. doi:10.1210/jc.85.8.2670
[6] R. Sih, et al., “Testosterone Replacement in Older Hypogonadal Men: A 12-Month Randomized Controlled Trial,” The Journal of Clinical Endocrinology & Metabolism, Vol. 82, No. 6, 1997, pp. 1661-1667. doi:10.1210/jc.82.6.1661
[7] A. M. Kenny, et al., “Effects of Transdermal Testosterone on Bone and Muscle in Older Men with Low Bioavailable Testosterone Levels,” The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, Vol. 56, No. 5, 2001, pp. 266-272. doi:10.1093/gerona/56.5.M266
[8] A. S. Dobs, et al., Pharmacokinetics, Efficacy, and Safety of a Permeation-Enhanced Testosterone Transdermal System in Comparison with Bi-Weekly Injections of Testosterone Enanthate for the Treatment of Hypogonadal Men. The Journal of Clinical Endocrinology & Metabolism, Vol. 84, No. 10, 1999, pp. 3469-3478. doi:10.1210/jc.84.10.3469
[9] P. P. J. Snyder, et al., “Effect of Testosterone Treatment on Bone Mineral Density in Men over 65 Years of Age,” The Journal of Clinical Endocrinology & Metabolism, Vol. 84, No. 6, 1999, pp. 1966-1972. doi:10.1210/jc.84.6.1966
[10] A. Morgentaler, “A 66-Year-Old Man with Sexual Dysfunction,” Journal of the American Medical Association, Vol. 291, No. 24, 2004, pp. 2994-3003. doi:10.1001/jama.291.24.2994
[11] C. Steidle, et al., “AA2500 Testosterone Gel Normalizes Androgen Levels in Aging Males with Improvements in Body Composition and Sexual Function,” The Journal of Clinical Endocrinology & Metabolism, Vol. 88, No. 6, 2003, pp. 2673-2681. doi:10.1210/jc.2002-021058
[12] M. C. Raynor, et al., “Androgen Deficiency in the Aging Male: A Guide to Diagnosis and Testosterone Replacement Therapy,” The Canadian Journal of Urology, Vol. 14, Suppl. 1, 2007, pp. 63-68.
[13] R. Shabsigh, “Testosterone Therapy in Erectile Dysfunction and Hypogonadism,” The Journal of Sexual Medicine, Vol. 2, No. 6, 2005, pp. 785-792. doi:10.1111/j.1743-6109.2005.00139.x
[14] S. Bhasin, et al., “Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline,” The Journal of Clinical Endocrinology and Metabolism, Vol. 95, No. 6, 2010, pp. 2536-2559. doi:10.1210/jc.2009-2354
[15] C. Wang, et al., “Investigation, Treatment, and Monitoring of Late-Onset Hypogonadism in Males: ISA, ISSAM, EAU, EAA, and ASA Recommendations,” European Urology, Vol. 55, No. 1, 2009, pp. 121-130. doi:10.1016/j.eururo.2008.08.033
[16] M. Carruthers, “The Paradox Dividing Testosterone Deficiency Symptoms and Androgen Assays: A Closer Look at the Cellular and Molecular Mechanisms of Androgen Action,” The Journal of Sexual Medicine, Vol. 5, No. 4, 2008, pp. 998-1012. doi:10.1111/j.1743-6109.2007.00721.x
[17] J. Bain, G. Brock and I. Kuzmarov, “Canadian Society for the Study of the Aging Male: Response to Health Canada’s Position Paper on Testosterone Treatment,” The Journal of Sexual Medicine, Vol. 4, No. 3, 2007, pp. 558-566. doi:10.1111/j.1743-6109.2007.00488.x
[18] C. Wang, et al., “Measurement of Total Serum Testosterone in Adult Men: Comparison of Current Laboratory Methods versus Liquid Chromatography-Tandem Mass Spectrometry,” The Journal of Clinical Endocrinology & Metabolism, Vol. 89, No. 2, 2004, pp. 534-543. doi:10.1210/jc.2003-031287
[19] S. Lazarou, L. Reyes-Vallejo and A. Morgentaler, “Wide Variability in Laboratory Reference Values for Serum Testosterone,” The Journal of Sexual Medicine, Vol. 3, No. 6, 2006, pp. 1085-1089. doi:10.1111/j.1743-6109.2006.00334.x
[20] N. Friedrich, et al., “Reference Ranges for Serum Dehydroepiandrosterone Sulfate and Testosterone in Adult Men,” Journal of Andrology, Vol. 29, No. 6, 2008, pp. 610-617. doi:10.2164/jandrol.108.005561
[21] H. A. Feldman, et al., “Age Trends in the Level of Serum Testosterone and Other Hormones in Middle-Aged Men: Longitudinal Results from the Massachusetts Male Aging Study,” The Journal of Clinical Endocrinology and Metabolism, Vol. 87, No. 2, 2002, pp. 589-598. doi:10.1210/jc.87.2.589
[22] S. M. Harman, et al., “Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men. Baltimore Longitudinal Study of Aging,” The Journal of Clinical Endocrinology and Metabolism, Vol. 86, No. 2, 2001, pp. 724-731. doi:10.1210/jc.86.2.724
[23] F. C. Wu, et al., “Hypothalamic-Pituitary-Testicular Axis Disruptions in Older Men Are Differentially Linked to Age and Modifiable Risk Factors: The European Male Aging Study,” The Journal of Clinical Endocrinology and Metabolism, Vol. 93, No. 7, 2008, pp. 2737-2745. doi:10.1210/jc.2007-1972
[24] A. M. Matsumoto and W. J. Bremner, “Serum Testosterone Assays—Accuracy Matters,” The Journal of Clinical Endocrinology & Metabolism, Vol. 89, No. 2, 2004, pp. 520-524. doi:10.1210/jc.2003-032175
[25] K. Sikaris, et al., “Reproductive Hormone Reference Intervals for Healthy Fertile Young Men: Evaluation of Automated Platform Assays,” The Journal of Clinical Endocrinology & Metabolism, Vol. 90, No. 11, 2005, pp. 5928-5936. doi:10.1210/jc.2005-0962
[26] J. Taieb, et al., “Testosterone Measured by 10 Immunoassays and by Isotope-Dilution Gas ChromatographyMass Spectrometry in Sera from 116 Men, Women, and Children,” Clinical Chemistry, Vol. 49, No. 8, 2003, pp. 1381-1395. doi:10.1373/49.8.1381
[27] M. J. Wheeler and S. C. Barnes, “Measurement of Testosterone in the Diagnosis of Hypogonadism in the Ageing Male,” Clinical Endocrinology, Vol. 69, No. 4, 2008, pp. 515-525. doi:10.1111/j.1365-2265.2008.03325.x
[28] A. Vermeulen, R. Rubens and L. Verdonck, “Testosterone Secretion and Metabolism in Male Senescence,” The Journal of Clinical Endocrinology & Metabolism, Vol. 34, No. 4, 1972, pp. 730-735. doi:10.1210/jcem-34-4-730
[29] R. Rubens, M. Dhont and A. Vermeulen, “Further Studies on Leydig Cell Function in Old Age,” The Journal of Clinical Endocrinology & Metabolism, Vol. 39, No. 1, 1974, pp. 40-45. doi:10.1210/jcem-39-1-40
[30] H. W. Baker, et al., “Changes in the Pituitary-Testicular System with Age,” Clinical Endocrinology, Vol. 5, No. 4, 1976, pp. 349-372. doi:10.1111/j.1365-2265.1976.tb01964.x
[31] K. M. Pirke and P. P. Doerr, “Age Related Changes in Free Plasma Testosterone, Dihydrotestosterone and Oestradiol,” Acta Endocrinologica (Copenhagen), Vol. 80, No. 1, 1975, pp. 171-178.
[32] F. E. Purifoy, L. H. Koopmans and D. M. Mayes, “Age Differences in Serum Androgen Levels in Normal Adult Males,” Human Biology, Vol. 53, No. 4, 1981, pp. 499-511.
[33] W. J. Bremner, M. V. Vitiello and P. P. N. Prinz, “Loss of Circadian Rhythmicity in Blood Testosterone Levels with Aging in Normal Men,” The Journal of Clinical Endocrinology & Metabolism, Vol. 56, No. 6, 1983, pp. 1278-1281. doi:10.1210/jcem-56-6-1278
[34] J. S. Tenover, et al., “The Effects of Aging in Normal Men on Bioavailable Testosterone and Luteinizing Hormone Secretion: Response to Clomiphene Citrate,” The Journal of Clinical Endocrinology & Metabolism, Vol. 65, No. 6, 1987, pp. 1118-1126. doi:10.1210/jcem-65-6-1118
[35] A. Gray, et al., “An Examination of Research Design Effects on the Association of Testosterone and Male Aging: Results of a Meta-Analysis,” Journal of Clinical Epidemiology, Vol. 44, No. 7, 1991, pp. 671-684. doi:10.1016/0895-4356(91)90028-8
[36] R. L. Ferrini and E. Barrett-Connor, “Sex Hormones and Age: A Cross-Sectional Study of Testosterone and Estradiol and Their Bioavailable Fractions in Community-Dwelling Men,” American Journal of Epidemiology, Vol. 147, No. 8, 1998, pp. 750-754. doi:10.1093/oxfordjournals.aje.a009519
[37] M. W. Elmlinger, et al., “Reference Intervals for Testosterone, Androstenedione and SHBG Levels in Healthy Females and Males from Birth until Old Age,” Clinical Laboratory, Vol. 51, No. 11-12, 2005, pp. 625-632.
[38] S. M. Harman and P. P. D. Tsitouras, “Reproductive Hormones in Aging Men. I. Measurement of Sex Steroids, Basal Luteinizing Hormone, and Leydig Cell Response to Human Chorionic Gonadotropin,” The Journal of Clinical Endocrinology & Metabolism, Vol. 51, No. 1, 1980, pp. 35-40. doi:10.1210/jcem-51-1-35
[39] E. Nieschlag, et al., “Reproductive Functions in Young Fathers and Grandfathers,” The Journal of Clinical Endocrinology & Metabolism, Vol. 55, No. 4, 1982, pp. 676-681. doi:10.1210/jcem-55-4-676
[40] A. Vermeulen, “Androgen Replacement Therapy in the Aging Male—A Critical Evaluation,” The Journal of Clinical Endocrinology & Metabolism, Vol. 86, No. 6, 2001, pp. 2380-2390. doi:10.1210/jc.86.6.2380
[41] J. E. Morley, et al., “Longitudinal Changes in Testosterone, Luteinizing Hormone, and Follicle-Stimulating Hormone in Healthy Older Men,” Metabolism, Vol. 46, No. 4, 1997, pp. 410-413. doi:10.1016/S0026-0495(97)90057-3
[42] D. S. Ooi, et al., “Establishing Reference Intervals for DPC’s Free Testosterone Radioimmunoassay,” Clinical Biochemistry, Vol. 31, No. 1, 1998, pp. 15-21. doi:10.1016/S0009-9120(97)00143-4
[43] H. N. Bui, et al., “Serum Testosterone Levels Measured by Isotope Dilution-Liquid Chromatography-Tandem Mass Spectrometry in Postmenopausal Women versus Those in Women Who Underwent Bilateral Oophorectomy,” Annals of Clinical Biochemistry, Vol. 47, No. 3, 2010, pp. 248-252. doi:10.1258/acb.2010.009171

Copyright © 2021 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.